Studies have reported that sunitinib treatment activates many resistance-associated pathways in renal cancer cells, such as the pERK-induced endoplasmic reticulum stress response pathway, PI3K/AKT signaling pathway, and NF-kappa B pathway 29. This evidence concerns the gene EIF2AK3 and renal carcinoma.